This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement
by Zacks Equity Research
Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) robust segmental performance and Cantel Medical buyout.
Abiomed's (ABMD) Impella Favored by Latest Study Result
by Zacks Equity Research
Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids
by Zacks Equity Research
With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
West Pharmaceutical's (WST) Latest Investment to Boost Business
by Zacks Equity Research
West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.
Charles River (CRL) Business Hurt by Macro and FX Headwinds
by Zacks Equity Research
In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
Zacks.com featured highlights include AMN Healthcare Services, Encore Wire and Global Ship
by Zacks Equity Research
AMN Healthcare Services, Encore Wire and Global Ship are part of Zacks Screen of the Week article.
Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
Zacks.com featured highlights include AMN Healthcare Services, Quanex Building Products, Sonoco and Super Micro Computer
by Zacks Equity Research
AMN Healthcare Services, Quanex Building Products, Sonoco and Super Micro Computer are part of Screen of the Week article.
3 Profitable Stocks to Buy on the Basis of Net Income Ratio
by Tirthankar Chakraborty
AMN Healthcare Services (AMN), Encore Wire (WIRE) and Global Ship Lease (GSL) have been selected as the top picks with a high net income ratio.
Wall Street Analysts Think AMN Healthcare (AMN) Could Surge 25%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for AMN Healthcare (AMN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.
Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered
by Zacks Equity Research
Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like AMN, NX, SON and SMCI that are seeing price strength have a high chance of carrying the momentum forward.
Best Momentum Stocks to Buy for August 9th
by Zacks Equity Research
AMN, BUSE and DNOW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 9, 2022.
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
Best Value Stocks to Buy for August 9th
by Zacks Equity Research
AMN, DOOO and NSIT made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 9, 2022.
AMN vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.
Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.